Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools, said, “With steadfast operating discipline, we continue to make important progress executing against our long-term strategic transformation plan, and we are excited to move forward as a combined company with SomaLogic. We are pleased that both companies delivered annual revenues above our stated targets, which we achieved in a challenging macroenvironment, and remain committed to building a scalable, profitable suite of differentiated life science tools and accelerating breakthroughs in health care.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LAB:
- Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue
- Standard BioTools trading halted, news dissemination
- Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools
- Standard BioTools completes merger with SomaLogic
- SomaLogic shareholders approve transaction with Standard BioTools